Supernus Pharmaceuticals, Inc. (SUPN)
SUPN Stock Price Chart
Explore Supernus Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SUPN price movements and trends.
SUPN Company Profile
Discover essential business fundamentals and corporate details for Supernus Pharmaceuticals, Inc. (SUPN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1 May 2012
Employees
674.00
Website
https://www.supernus.comCEO
Jack A. Khattar
Description
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
SUPN Financial Timeline
Browse a chronological timeline of Supernus Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.43, while revenue estimate is $205.60m.
Earnings released on 5 May 2026
EPS came in at $0.59 surpassing the estimated $0.28 by +110.71%, while revenue for the quarter reached $207.71m , beating expectations by +7.67%.
Earnings released on 24 Feb 2026
EPS came in at $0.92 surpassing the estimated $0.28 by +228.57%, while revenue for the quarter reached $211.57m , beating expectations by +8.41%.
Earnings released on 4 Nov 2025
EPS came in at $1.01 surpassing the estimated $0.82 by +23.17%, while revenue for the quarter reached $192.10m , missing expectations by -1.35%.
Earnings released on 5 Aug 2025
EPS came in at $0.91 surpassing the estimated $0.47 by +93.62%, while revenue for the quarter reached $165.45m , missing expectations by -1.65%.
Earnings released on 6 May 2025
EPS came in at $0.42 surpassing the estimated $0.38 by +10.53%, while revenue for the quarter reached $149.82m , beating expectations by +1.28%.
Earnings released on 25 Feb 2025
EPS came in at $0.75 surpassing the estimated $0.46 by +63.04%, while revenue for the quarter reached $174.16m , beating expectations by +12.18%.
Earnings released on 4 Nov 2024
EPS came in at $1.06 surpassing the estimated $0.39 by +171.79%, while revenue for the quarter reached $175.69m , beating expectations by +13.70%.
Earnings released on 6 Aug 2024
EPS came in at $0.36 surpassing the estimated $0.31 by +16.13%, while revenue for the quarter reached $168.33m , beating expectations by +13.08%.
Earnings released on 8 May 2024
EPS came in at $0.26 falling short of the estimated $0.38 by -31.58%, while revenue for the quarter reached $143.64m , missing expectations by -1.50%.
Earnings released on 27 Feb 2024
EPS came in at $0.02 falling short of the estimated $0.41 by -95.12%, while revenue for the quarter reached $164.31m , beating expectations by +5.99%.
Earnings released on 8 Nov 2023
EPS came in at -$0.29 falling short of the estimated $0.13 by -323.08%, while revenue for the quarter reached $153.88m , missing expectations by -0.90%.
Earnings released on 8 Aug 2023
EPS came in at -$0.02 falling short of the estimated $0.23 by -108.70%, while revenue for the quarter reached $135.56m , missing expectations by -5.64%.
Earnings released on 9 May 2023
EPS came in at $0.29 surpassing the estimated $0.17 by +70.59%, while revenue for the quarter reached $153.76m , beating expectations by +10.61%.
Earnings released on 28 Feb 2023
EPS came in at $0.43 falling short of the estimated $0.68 by -36.76%, while revenue for the quarter reached $167.33m , missing expectations by -7.21%.
Earnings released on 8 Nov 2022
EPS came in at $0.03 falling short of the estimated $0.36 by -91.67%, while revenue for the quarter reached $177.35m , beating expectations by +2.83%.
Earnings released on 4 Aug 2022
EPS came in at $0.14 falling short of the estimated $0.29 by -51.72%, while revenue for the quarter reached $170.05m , beating expectations by +3.61%.
Earnings released on 9 May 2022
EPS came in at $0.43 surpassing the estimated $0.26 by +65.38%, while revenue for the quarter reached $152.51m , missing expectations by -0.91%.
Earnings released on 28 Feb 2022
EPS came in at $0.04 falling short of the estimated $0.24 by -81.34%, while revenue for the quarter reached $159.05m , beating expectations by +7.19%.
Earnings released on 3 Nov 2021
EPS came in at $0.40 surpassing the estimated $0.23 by +73.91%, while revenue for the quarter reached $148.46m , beating expectations by +25.70%.
Earnings released on 4 Aug 2021
EPS came in at $0.43 surpassing the estimated $0.20 by +115.00%, while revenue for the quarter reached $141.33m , beating expectations by +4.79%.
SUPN Stock Performance
Access detailed SUPN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
